A clinical study to evaluate the comparative efficacy of three Unani drugs in the treatment of Hepatitis B carriers

Evaluation of Therapeutic Efficacy and Safety of coded Unani Drugs PTH-1, PTH-2 and PTH-3 in Asymptomatic Hepatitis B Carriers

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/06/014642

Enrollment

Registered

2018-06-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Asymptomatic Hepatitis B Carrier State

Interventions

Intervention1: PTH-1: PTH-1: two Capsules (500 mg each) thrice daily for 06 months Intervention2: PTH-2: PTH-2: two Capsules (500 mg each) thrice daily for 06 months Intervention3: PTH-3: PTH-3: two

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of any Gender aged 20-60 years 2. HBsAg-Positive Asymptomatic Cases 3. Viral Load

Exclusion criteria

Exclusion criteria: 1. Viral Load: >20,000 IU/mL 2. Active Hepatitis 3. Patients on Immune Suppressants Therapy 4. History of Severe Systemic Disease 5. H/o of Drug or Alcohol Abuse, Chronic Smokers not willing to abstain from smoking during the study period 6. Subjects with known allergies 7. Receiving any other Investigational Product

Design outcomes

Primary

Measure	Time frame
1. Clearance of HBsAg 2. Reduction in viral load (Serum HBV DNA estimation by PCR)Timepoint: 3 months and 6 months	—

Secondary

Measure	Time frame
Safety Assessment by adverse events (LFT & KFT)Timepoint: at every month	—

Countries

India

Contacts

Public ContactProf Qamar Uddin

Central Research Institute of Unani Medicine

qamaruddindr@gmail.com8800662546

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026